Form 4: Jazz Pharmaceuticals Executive Samantha Pearce Reports Stock Transaction
SEC Form 4 Filing
Samantha Pearce, SVP, Head of Europe & International at Jazz Pharmaceuticals, reports the disposal of 2,474 ordinary shares to cover tax obligations.
Summary
- On March 5, 2024, Samantha Pearce, SVP, Head of Europe & International at Jazz Pharmaceuticals, disposed of 2,474 ordinary shares.
- The transaction was executed to cover tax obligations arising from the vesting of restricted stock units.
- The shares were sold at a price of $117.53.
- Following the transaction, Pearce directly owns 16,922 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a neutral report of a stock transaction. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for executives at publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale of shares by an executive to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of stock transaction (disposal of shares) |
| 03/07/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.